EA202092030A1 - Офтальмологическая композиция, включающая диквафозол и катионный полимер - Google Patents

Офтальмологическая композиция, включающая диквафозол и катионный полимер

Info

Publication number
EA202092030A1
EA202092030A1 EA202092030A EA202092030A EA202092030A1 EA 202092030 A1 EA202092030 A1 EA 202092030A1 EA 202092030 A EA202092030 A EA 202092030A EA 202092030 A EA202092030 A EA 202092030A EA 202092030 A1 EA202092030 A1 EA 202092030A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cationic
copolymer
hydrolyzed
polymer
ophthalmic composition
Prior art date
Application number
EA202092030A
Other languages
English (en)
Russian (ru)
Inventor
Киохеи Такахаси
Хироюки Асада
Асука Камимура
Кендзи Морисима
Юсуке Момокава
Кенити Эндо
Original Assignee
Сантен Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантен Фармасьютикал Ко., Лтд. filed Critical Сантен Фармасьютикал Ко., Лтд.
Publication of EA202092030A1 publication Critical patent/EA202092030A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EA202092030A 2018-02-28 2019-02-27 Офтальмологическая композиция, включающая диквафозол и катионный полимер EA202092030A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018035578 2018-02-28
PCT/JP2019/007542 WO2019168023A1 (ja) 2018-02-28 2019-02-27 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物

Publications (1)

Publication Number Publication Date
EA202092030A1 true EA202092030A1 (ru) 2020-11-16

Family

ID=67806273

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092030A EA202092030A1 (ru) 2018-02-28 2019-02-27 Офтальмологическая композиция, включающая диквафозол и катионный полимер

Country Status (14)

Country Link
US (1) US20210000844A1 (https=)
EP (1) EP3760207A4 (https=)
JP (5) JP6716800B2 (https=)
KR (3) KR20250053220A (https=)
CN (2) CN111757742B (https=)
BR (1) BR112020017661A2 (https=)
CA (1) CA3091700A1 (https=)
EA (1) EA202092030A1 (https=)
MX (2) MX2020008925A (https=)
PH (1) PH12020551313B1 (https=)
SG (1) SG11202007977RA (https=)
TW (4) TW202600146A (https=)
UA (1) UA129517C2 (https=)
WO (1) WO2019168023A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12020551313B1 (en) * 2018-02-28 2024-02-28 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
JP7526718B2 (ja) * 2019-02-27 2024-08-01 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
KR102656181B1 (ko) * 2019-08-27 2024-04-08 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN113712910A (zh) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 一种滴眼液及其制备方法
EP4393510A4 (en) * 2021-09-30 2025-08-06 Rohto Pharma OPHTHALMOLOGICAL COMPOSITION
KR102794468B1 (ko) 2022-04-04 2025-04-14 서울대학교산학협력단 감미 억제용 조성물 및 식품의 감미 억제 방법
KR20250038935A (ko) * 2023-09-13 2025-03-20 루다큐어 주식회사 8-옥소-2'-데옥시구아노신 또는 이의 약학적으로 허용가능한 염을 포함하는 수용액 형태의 점안제
KR20250160050A (ko) 2024-05-03 2025-11-11 삼천당제약주식회사 물리화학적 특성이 개선된 안구건조증 예방 또는 치료용 약학 조성물
CN119970633A (zh) * 2025-03-26 2025-05-13 苏州乐珠制药有限公司 一种地夸磷索钠滴眼液及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294620A (ja) 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd 水溶液製剤およびその製造方法
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3155689B2 (ja) * 1995-08-10 2001-04-16 昭和薬品化工株式会社 消炎点眼剤
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
KR20010013797A (ko) 1997-07-25 2001-02-26 인스파이어 파마슈티컬스 인코퍼레이티드 디(우리딘 5'-테트라포스페이트) 염 및 그의 제조방법과용도
JP2001294620A (ja) 2000-04-11 2001-10-23 Showa Denko Kk プラスチックレンズ材料、該材料の製造方法、プラスチックレンズ用組成物、該組成物を硬化してなるプラスチックレンズ、及び該プラスチックレンズの製造方法
BR0111297A (pt) * 2000-05-30 2004-01-06 Santen Pharmaceutical Co Ltd Promotor de migração epitelial corneana
KR101484499B1 (ko) * 2005-02-14 2015-01-20 존슨 앤드 존슨 비젼 케어, 인코포레이티드 안과용 렌즈의 제조방법, 안과용 장치 및 콘택트 렌즈
JP4515960B2 (ja) 2005-05-19 2010-08-04 株式会社資生堂 整髪料洗浄剤及びその使用方法
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
CA2717825A1 (en) * 2008-03-07 2009-09-11 Sun Pharma Advanced Research Company Ltd. Opthalmic composition
MX2013007502A (es) * 2010-12-28 2013-08-01 Santen Pharmaceutical Co Ltd Solucion oftalmica que comprende diquafosol, metodo para producir la misma, y metodo para inhibir la formacion de precipitado insoluble.
EP3431092A1 (en) * 2012-03-26 2019-01-23 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
CN106456536B (zh) * 2014-05-07 2020-05-12 克罗马药品股份有限公司 水性眼用溶液和治疗干眼综合征的方法
JPWO2015190483A1 (ja) * 2014-06-10 2017-04-20 ロート製薬株式会社 眼科用水性組成物
TWI709405B (zh) * 2014-12-25 2020-11-11 日商參天製藥股份有限公司 水性點眼液及其應用
KR101587385B1 (ko) 2015-07-29 2016-01-21 국제약품공업주식회사 사이클로스포린 함유 무자극성의 안약조성물 및 편리한 제조방법
WO2017033967A1 (ja) * 2015-08-24 2017-03-02 参天製薬株式会社 眼科用フィルム製剤
EP3266446B1 (en) * 2016-07-07 2018-11-21 Laboratorios SALVAT, S.A. Ophthalmic composition comprising castor oil and medium chain triglyceride
CN106772747B (zh) * 2016-12-26 2022-10-18 深圳市光科全息技术有限公司 一种光学膜及其制作方法
MY196323A (en) * 2017-04-25 2023-03-24 Wakamoto Pharma Co Ltd Thermo-Responsive Gelling Artificial Lacrima
JP6582029B2 (ja) * 2017-10-03 2019-09-25 株式会社メニコン 眼科用組成液及びその使用方法
PH12020551313B1 (en) * 2018-02-28 2024-02-28 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
JP7526718B2 (ja) * 2019-02-27 2024-08-01 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
KR102656181B1 (ko) * 2019-08-27 2024-04-08 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물

Also Published As

Publication number Publication date
JP2020138980A (ja) 2020-09-03
KR20250053220A (ko) 2025-04-21
TW202600146A (zh) 2026-01-01
JP7297718B2 (ja) 2023-06-26
CN111757742B (zh) 2023-09-26
TW202423451A (zh) 2024-06-16
CN117137866A (zh) 2023-12-01
TW202306572A (zh) 2023-02-16
KR20200127002A (ko) 2020-11-09
US20210000844A1 (en) 2021-01-07
KR102796051B1 (ko) 2025-04-14
MX2020008925A (es) 2020-10-01
CA3091700A1 (en) 2019-09-06
JP2026034664A (ja) 2026-02-27
JP2022136152A (ja) 2022-09-15
TWI898399B (zh) 2025-09-21
EP3760207A1 (en) 2021-01-06
CN111757742A (zh) 2020-10-09
SG11202007977RA (en) 2020-09-29
JPWO2019168023A1 (ja) 2020-05-28
WO2019168023A1 (ja) 2019-09-06
TW202000212A (zh) 2020-01-01
JP2024045506A (ja) 2024-04-02
TWI781296B (zh) 2022-10-21
BR112020017661A2 (pt) 2020-12-22
EP3760207A4 (en) 2023-10-04
JP7472202B2 (ja) 2024-04-22
TWI833406B (zh) 2024-02-21
JP6716800B2 (ja) 2020-07-01
UA129517C2 (uk) 2025-05-21
JP7796782B2 (ja) 2026-01-09
MX2022014791A (es) 2023-01-16
PH12020551313A1 (en) 2021-09-06
KR20220163519A (ko) 2022-12-09
PH12020551313B1 (en) 2024-02-28
KR102472773B1 (ko) 2022-11-30

Similar Documents

Publication Publication Date Title
EA202092030A1 (ru) Офтальмологическая композиция, включающая диквафозол и катионный полимер
BR112018072343A2 (pt) método de determinação de um filtro para uma lente oftálmica em função de uma grandeza representativa de uma sensibilidade dinâmica do olho de um portador a uma variação de um fluxo luminoso
PE20190433A1 (es) Vacuna contra vrs
ZA202306237B (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
JOP20210106A1 (ar) بروتينات rsv f سابقة الاندماج مستقرة
BR112019000178A2 (pt) hidrogéis de silicone compreendendo n-alquil metacrilamidas e lentes de contato produzidas a partir dos mesmos
MX387353B (es) Amidas heterocíclicas útiles como moduladores de proteínas.
CY1125184T1 (el) Enωσεις
BR112017018491A2 (pt) hidrolisados de proteína à base de leite e composições produzidas a partir dos mesmos
WO2004004757A8 (en) Treatment for eye disorder
FR3052977B1 (fr) Composition comprenant au moins un polymere acrylate et au moins une silicone choisie parmi les silicones fonctionalisees par au moins un groupement mercapto ou thiol
EP3515444A4 (en) COMPOSITION FOR TREATING EYE DISEASES AND METHOD FOR USE AND PRODUCTION
EP3765095A4 (en) OPHTHALMIC COMPOSITIONS OF INDIGO-CARMINE AND EYEPIECES USES THEREOF
EA202191212A1 (ru) Композиции и способы для обработки биопленок без индуцирования резистентности к противомикробным препаратам
MY197057A (en) Method for producing silicone hydrogel contact lenses
CY1124640T1 (el) Μια meθοδος αντιμετωπισης μυκητιασικων μολυνσεων
CL2021002992A1 (es) Métodos y composiciones que comprenden variantes de la proteína a de estafilococos (spa)
PT3660545T (pt) Composição de hidrogel de silicone, lente de hidrogel de silicone, e método de fabrico de lente de hidrogel de silicone
BR112015028726A2 (pt) sistema e método para programar uma lente oftálmica energizada
EA202192543A1 (ru) Вектор и способ для лечения синдрома ангельмана
BR112015029954A2 (pt) composição e processo para tratar as fibras queratínicas
BR0204921A (pt) Uso de silicones aminados particulares em pré- ou pós-tratamento de descoloração de fibras queratìnicas e processo de descoloração das mesmas
BR112018072818A2 (pt) copolímero de bloco de silicone, processo para preparação de um copolímero, emulsão, método para tratamento de um substrato, composição para cuidados pessoais, xampu, condicionador para cabelos, uso da emulsão, e, composição anidra de tratamento capilar sem enxágue
TH2001004832A (th) องค์ประกอบสำหรับหยอดตาที่ประกอบรวมด้วยไดควาโฟซอลและพอลิเมอร์ประจุบวก
EP3905987A4 (en) DENTAL IMPLANTS, DENTAL IMPLANT SYSTEMS, AND METHODS OF MAKING AND USE THEREOF